Related Experiment Video
Updated: May 11, 2026
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Ramucirumab: a novel antiangiogenic agent
Roopma Wadhwa1, Takashi Taketa, Kazuki Sudo
1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA.
Future Oncology (London, England)
|May 31, 2013
Summary
Ramucirumab targets VEGFR2 to inhibit tumor growth and metastasis. Its selectivity for VEGFR2 may improve safety and efficacy in cancer therapy, particularly for gastric cancer.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Ramucirumab is a fully humanized monoclonal antibody targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2).
- Angiogenesis, driven by VEGFR2, is crucial for tumor growth and metastasis.
- Existing anti-angiogenesis agents have varying safety and efficacy profiles.
Purpose of the Study:
- To describe the mechanism of action, pharmacokinetics, safety, and clinical trial results of ramucirumab.
- To highlight ramucirumab's potential benefits due to its selectivity for VEGFR2.
- To focus on the application of ramucirumab in gastric cancer treatment.
Main Methods:
- Review of preclinical and clinical data on ramucirumab.
- Analysis of ramucirumab's binding affinity and downstream signaling inhibition.
- Evaluation of pharmacokinetic and safety data from clinical trials.
- Assessment of efficacy in gastric cancer patients.
Main Results:
- Ramucirumab effectively binds to VEGFR2, inhibiting angiogenesis.
- Its selectivity for VEGFR2 may lead to an improved safety profile compared to less selective agents.
- Clinical trials demonstrate ramucirumab's activity, particularly in gastric cancer.
Conclusions:
- Ramucirumab's VEGFR2 selectivity offers a promising therapeutic strategy.
- The drug exhibits a favorable safety and efficacy profile for cancer treatment.
- Ramucirumab represents a significant advancement in anti-angiogenesis therapy for gastric cancer.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...